Positive Results Announced for Phase III Clinical Trial of Evofem Hormone-Free Birth Control Product; Meridian Site Involved
Evofem Biosciences, Inc. (NASDAQ: EVFM) (“Evofem” or the “Company”) today announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint. AMPOWER assessed the efficacy, safety and subject satisfaction with Amphora in approximately 1,400 healthy women aged 18-35 years at 112 centers in the U.S. The primary endpoint of the study was the pregnancy rate over seven cycles of use (one cycle = 21-35 days) as assessed by the Kaplan-Meier statistical method. Top-line data analysis demonstrates a cumulative pregnancy rate of 14.0% over seven cycles of use (95% CI 10.0, 18.0). … Read more
Michael Hemphill, MD, Receives Health Professional Impact Award from the National Multiple Sclerosis Society
Savannah, Ga., December 10, 2018 — Michael Hemphill, MD, has received the 2018 Health Professional Impact Award from the National Multiple Sclerosis Society (NMSS). He is a principal investigator at Meridian Clinical Research, and has been a physician at Savannah Neurology Specialists in Savannah, Ga., since 1981. The NMSS Health Professional Impact Award honors health professionals who have demonstrated their commitment to helping people with the challenges of multiple sclerosis by providing high-quality clinical care and serving in volunteer leadership positions. Dr. Hemphill received this award at an event in Atlanta, Ga. As a patient advocate for those afflicted with … Read more
Meridian to Celebrate Annual ‘Good Deeds Day’ by Giving Back to Several Communities
Omaha, Neb., December 3, 2018 — Throughout the week of December 3-7, each Meridian Clinical Research location will celebrate a Good Deeds Day. This year’s activities will be held across all of Meridian’s 15 U.S. research sites, four remote offices, two call centers, and corporate office. For Good Deeds Day, employees at each Meridian site are given a cash stipend and a simple instruction: Go into your community and make a difference. Meridian employees decide on the best way to donate to the community, support local charities, or perform small acts of kindness. This tradition of spontaneous giving began more … Read more
Brandon Essink, MD, to Lead a Roundtable Discussion at World Vaccine Congress in Lisbon, Portugal
Omaha, Neb., October 24, 2018 — Meridian Clinical Research will attend the 19th World Vaccine Congress (WVC) in Lisbon, Portugal from October 29 to 31. As a leading investigative site network for vaccines and infectious diseases, Meridian will have several representatives at the conference.
Meridian Helps Raise Almost $20,000 in First MDA Golf Classic
Meridian recently sponsored its first golf event with Muscular Dystrophy Association (MDA) at the Tiburon Golf Club in Omaha, NE. The event raised almost $20,000 to support future research and MDA Summer Camp. Thank you to everyone who participated — see you next year! The second MDA Golf Classic sponsored by Meridian is scheduled for September 18, 2019, at the Tiburon Golf Club.
Meridian Named an SCRS Global Summit Site Tank Finalist
Ellicott City, MD, September 25, 2018 – Today the Society for Clinical Research Sites (SCRS) announced the finalists for the 2018 Site Tank. Site Tank™ is a competition for sites to submit their innovative technology ideas that would enhance, empower and improve clinical research operations and transform business models. Congratulations to the 2018 finalists: Amici Clinical Research, Envision Physician Clinical Research and Meridian Clinical Research. The finalists will present their tech ideas at the Global Site Solutions Summit in Boca Raton, FL October 12-14, 2018. A judging panel made up of executives from the clinical research industry will select the winning presentation. [Meridian’s Andrew … Read more
Eight Meridian Investigators Voted ‘Best of Savannah’ by Savannah Magazine Readers
SAVANNAH, GA. (PRWEB) SEPTEMBER 19, 2018 — Seven physicians and one physician assistant that serve as principal investigators for Meridian Clinical Research have won a ‘Best of Savannah Doctors 2018’ award. The award winners were determined by reader votes and are featured in the September/October issue of Savannah Magazine.
Meridian Principal Investigator Corinne Howington, MD, Conducted Research for Acne Product That Receives FDA Clearance
Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles. This significant achievement is a milestone in the treatment of acne and follows the company’s completion of its pivotal study, which clearly demonstrated clinical efficacy and safety of Sebacia Microparticles, and its 510(k) submission to the FDA in June 2018. In partnership with Meridian Clinical Research, Corinne Howington, MD, led a clinical study for this product at Low Country Dermatology in Savannah, GA. Meridian congratulates Dr. Howington and her team. Read … Read more
Results From Meridian Clinical Research Studies Featured in Prestigious Publications and Academic Presentations
OMAHA, NEB., NORFOLK, NEB., AND SAVANNAH, GA. (PRWEB LINK) AUGUST 16, 2018 Results from clinical trials performed at Meridian Clinical Research sites in Norfolk, Neb., Omaha, Neb., and Savannah, Ga., were recently published in two prestigious medical journals. Dr. Brandon Essink, Meridian’s medical director and principal investigator, co-authored an article published in Vaccine. Dr. Essink led a study at Meridian’s Omaha, Neb., site as part of a successful clinical trial for a vaccine found to provide broad protection against meningococcal disease (meningitis).
Dr. Brandon Essink Co-Authors Article Published in the Journal, Vaccine
Meridian Medical Director and Principal Investigator Dr. Brandon Essink co-authored an article recently published in the prestigious journal, Vaccine. A successful meningococcal disease vaccine trial led to this publication, which you can read now at: https://lnkd.in/dGCjtRH Title: Breadth of Coverage Against a Panel of 110 Invasive Disease Isolates, Immunogenicity and Safety for 2 and 3 Doses of an Investigational MenABCWY Vaccine in US Adolescents – Results From a Randomized, Controlled, Observer-Blind Phase II Study